Is Cartesian Therapeutics, Inc. (RNAC) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 7.9% / 30% | 119.4% / 30% | 0.5% / 30% | 18.98% / 5% | ✗ NOT HALAL |
| DJIM | 7.9% / 33% | 119.4% / 33% | 0.5% / 33% | 18.98% / 5% | ✗ NOT HALAL |
| MSCI | 3.2% / 33% | 48.9% / 33% | 0.2% / 33% | 18.98% / 5% | ✗ NOT HALAL |
| S&P | 7.9% / 33% | 119.4% / 33% | 0.5% / 33% | 18.98% / 5% | ✗ NOT HALAL |
| FTSE | 3.2% / 33% | 48.9% / 33% | 0.2% / 50% | 18.98% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -2316.7% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -14.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$24M |
| Free Cash Flow | -$33M |
| Total Debt | $14M |
| Current Ratio | 8.7 |
| Total Assets | $435M |
Price & Trading
| Last Close | $6.08 |
| 50-Day MA | $7.10 |
| 200-Day MA | $8.97 |
| Avg Volume | 191K |
| Beta | 0.2 |
|
52-Week Range
$5.60
| |
About Cartesian Therapeutics, Inc. (RNAC)
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Cartesian Therapeutics, Inc. (RNAC) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Cartesian Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Cartesian Therapeutics, Inc.'s debt ratio?
Cartesian Therapeutics, Inc.'s debt ratio is 7.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 3.2%.
What are Cartesian Therapeutics, Inc.'s key financial metrics?
Cartesian Therapeutics, Inc. has a market capitalization of $155M, and revenue of $39M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.